Evis Hursever joined EW in 2011 and became Managing Director in 2019.
Dr. Hursever led EW’s growth equity investments in Cognate Bioservices (acquired by Charles River Laboratories), Laboratoires Majorelle, Grundium and GermFree and chairs the Board of Directors at Grundium and GermFree. She has played a key role and served on the Board of Directors of EW growth equity portfolio companies EUSA Pharma II (acquired by Recordati), and Biotoscana (acquired by Knight Therapeutics).
Prior to joining EW, Dr. Hursever had over 10 years of experience in the healthcare industry. She was a senior manager in the European life sciences and healthcare team at LEK Consulting, a management consulting company. She was involved in several business transactions in the healthcare space, developed growth strategies for several pharmaceutical companies, and led numerous due diligence assignments for private equity firms in the healthcare industry. Prior to LEK Consulting, Dr. Hursever worked in the healthcare investment banking team at Merrill Lynch International providing M&A advisory services to a broad range of life sciences and healthcare companies.
Dr. Hursever received her Bachelor of Arts degree from Macalester College and her PhD degree from the University of Pennsylvania.